{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:11:02Z","timestamp":1790691062520,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018R1A2B6005559"],"award-info":[{"award-number":["NRF-2018R1A2B6005559"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tumor immune microenvironment plays a crucial role in tumor progression. We performed immune profiling to compare immune-related gene expression between ductal carcinoma in situ (DCIS) and invasive carcinoma of the breast using nCounter PanCancer immune Profiling Panel and found that CXCL10 was the most significant gene that had the highest difference in expression between them. Effect of CXCL10 on breast cancer cell proliferation and invasion was examined in vitro, and expression of CXCL10 and its relationship with immune cell infiltration was assessed in breast cancer samples. CXCL10 induced cell proliferation, migration and epithelial-mesenchymal transition in MCF-7 and MDA-MB-231 breast cancer cell lines. We confirmed that CXCL10 mRNA expression was significantly higher in invasive carcinoma than in DCIS, especially in hormone receptor (HR)-negative tumors using a validation set. CXCL10 mRNA expression showed a positive correlation with tumor infiltrating lymphocyte (TIL) density in both DCIS and invasive carcinoma; CXCL10-positive tumors generally showed higher infiltration of CD8+\u2009and FOXP3+TILs as well as PD-L1+\u2009immune cells compared to CXCL10-negative tumors, albeit with different patterns according to HR status. In conclusion, our study showed that CXCL10 promotes tumor cell proliferation, invasion, and immune cell infiltration, implying its contribution in the progression of DCIS to invasive carcinoma of the breast.<\/jats:p>","DOI":"10.1038\/s41598-021-97390-5","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T10:06:24Z","timestamp":1631181984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast"],"prefix":"10.1038","volume":"11","author":[{"given":"Milim","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Yeon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yul Ri","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"97390_CR1","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1172\/JCI31405","volume":"117","author":"JB Swann","year":"2007","unstructured":"Swann, J. B. & Smyth, M. J. Immune surveillance of tumors. J. Clin. Invest. 117, 1137\u20131146 (2007).","journal-title":"J. Clin. Invest."},{"key":"97390_CR2","doi-asserted-by":"crossref","unstructured":"Chen, X.Y., Yeong, J., Thike, A.A., Bay, B.H. & Tan, P.H. Prognostic role of immune infiltrates in breast ductal carcinoma in situ. Breast Cancer Res. Treatment (2019).","DOI":"10.1007\/s10549-019-05272-2"},{"key":"97390_CR3","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nm.3944","volume":"21","author":"G Kroemer","year":"2015","unstructured":"Kroemer, G., Senovilla, L., Galluzzi, L., Andre, F. & Zitvogel, L. Natural and therapy-induced immunosurveillance in breast cancer. Nat. Med. 21, 1128\u20131138 (2015).","journal-title":"Nat. Med."},{"key":"97390_CR4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJM199802123380706","volume":"338","author":"AD Luster","year":"1998","unstructured":"Luster, A. D. Chemokines\u2013chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338, 436\u2013445 (1998).","journal-title":"N. Engl. J. Med."},{"key":"97390_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nri722","volume":"2","author":"AE Proudfoot","year":"2002","unstructured":"Proudfoot, A. E. Chemokine receptors: multifaceted therapeutic targets. Nat. Rev. Immunol. 2, 106\u2013115 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"97390_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cyto.2018.02.012","volume":"109","author":"N Karin","year":"2018","unstructured":"Karin, N. & Razon, H. Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokine 109, 24\u201328 (2018).","journal-title":"Cytokine"},{"key":"97390_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13058-020-01267-w","volume":"22","author":"M Kim","year":"2020","unstructured":"Kim, M. et al. Immune microenvironment in ductal carcinoma in situ: A comparison with invasive carcinoma of the breast. Breast Cancer Res.: BCR 22, 32 (2020).","journal-title":"Breast Cancer Res.: BCR"},{"key":"97390_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0065-2776(07)96002-2","volume":"96","author":"JR Schoenborn","year":"2007","unstructured":"Schoenborn, J. R. & Wilson, C. B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 96, 41\u2013101 (2007).","journal-title":"Adv. Immunol."},{"key":"97390_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga, R. et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2014A target for novel cancer therapy. Cancer Treat. Rev. 63, 40\u201347 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"97390_CR10","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1189\/jlb.0306212","volume":"80","author":"X Yang","year":"2006","unstructured":"Yang, X., Chu, Y., Wang, Y., Zhang, R. & Xiong, S. Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity. J. Leukoc. Biol. 80, 1434\u20131444 (2006).","journal-title":"J. Leukoc. Biol."},{"key":"97390_CR11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1158\/1078-0432.CCR-11-3314","volume":"19","author":"AM Mulligan","year":"2013","unstructured":"Mulligan, A. M. et al. Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clin. Cancer Res. 19, 336\u2013346 (2013).","journal-title":"Clin. Cancer Res."},{"key":"97390_CR12","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/leu.2014.121","volume":"28","author":"U Barash","year":"2014","unstructured":"Barash, U. et al. Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia 28, 2178\u20132187 (2014).","journal-title":"Leukemia"},{"key":"97390_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/1535-7163.MCT-08-0485","volume":"8","author":"X Ma","year":"2009","unstructured":"Ma, X. et al. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol. Cancer Ther. 8, 490\u2013498 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"97390_CR14","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-03-1757","volume":"64","author":"K Kawada","year":"2004","unstructured":"Kawada, K. et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Can. Res. 64, 4010\u20134017 (2004).","journal-title":"Can. Res."},{"key":"97390_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.yexmp.2015.06.002","volume":"99","author":"AA Ejaeidi","year":"2015","unstructured":"Ejaeidi, A. A., Craft, B. S., Puneky, L. V., Lewis, R. E. & Cruse, J. M. Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis. Exp. Mol. Pathol. 99, 163\u2013172 (2015).","journal-title":"Exp. Mol. Pathol."},{"key":"97390_CR16","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1158\/0008-5472.CAN-06-3087","volume":"67","author":"A Zipin-Roitman","year":"2007","unstructured":"Zipin-Roitman, A. et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Can. Res. 67, 3396\u20133405 (2007).","journal-title":"Can. Res."},{"key":"97390_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10549-014-2933-7","volume":"145","author":"E Hilborn","year":"2014","unstructured":"Hilborn, E. et al. C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients. Breast Cancer Res. Treat. 145, 73\u201382 (2014).","journal-title":"Breast Cancer Res. Treat."},{"key":"97390_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.imlet.2003.10.020","volume":"92","author":"L Goldberg-Bittman","year":"2004","unstructured":"Goldberg-Bittman, L. et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol. Lett. 92, 171\u2013178 (2004).","journal-title":"Immunol. Lett."},{"key":"97390_CR19","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2217\/fon.09.94","volume":"5","author":"DS Micalizzi","year":"2009","unstructured":"Micalizzi, D. S. & Ford, H. L. Epithelial\u2013mesenchymal transition in development and cancer. Future Oncol. 5, 1129\u20131143 (2009).","journal-title":"Future Oncol."},{"key":"97390_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.molonc.2010.11.003","volume":"5","author":"A Prat","year":"2011","unstructured":"Prat, A. & Perou, C. M. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 5, 5\u201323 (2011).","journal-title":"Mol Oncol."},{"key":"97390_CR21","doi-asserted-by":"crossref","unstructured":"Felipe Lima, J., Nofech-Mozes, S., Bayani, J. & Bartlett, J.M.S. EMT in Bbreast carcinoma\u2014A review. J. Clin. Med. 5, 65 (2016).","DOI":"10.3390\/jcm5070065"},{"key":"97390_CR22","first-page":"2824","volume":"9","author":"T Ren","year":"2017","unstructured":"Ren, T., Zhu, L. & Cheng, M. CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma. Am. J. Transl. Res. 9, 2824\u20132837 (2017).","journal-title":"Am. J. Transl. Res."},{"key":"97390_CR23","doi-asserted-by":"publisher","first-page":"9509","DOI":"10.1158\/0008-5472.CAN-05-4345","volume":"66","author":"D Datta","year":"2006","unstructured":"Datta, D. et al. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Can. Res. 66, 9509\u20139518 (2006).","journal-title":"Can. Res."},{"key":"97390_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1084\/jem.184.3.963","volume":"184","author":"M Loetscher","year":"1996","unstructured":"Loetscher, M. et al. Chemokine receptor specific for IP10 and mig: Structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184, 963\u2013969 (1996).","journal-title":"J. Exp. Med."},{"key":"97390_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/icb.2010.158","volume":"89","author":"JR Groom","year":"2011","unstructured":"Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207\u2013215 (2011).","journal-title":"Immunol. Cell Biol."},{"key":"97390_CR26","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jhep.2016.05.032","volume":"65","author":"CX Li","year":"2016","unstructured":"Li, C. X. et al. CXCL10\/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. J. Hepatol. 65, 944\u2013952 (2016).","journal-title":"J. Hepatol."},{"key":"97390_CR27","doi-asserted-by":"crossref","unstructured":"Lunardi, S., Lim, S.Y., Muschel, R.J. & Brunner, T.B. IP-10\/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer. Oncoimmunology 4, e1027473 (2015).","DOI":"10.1080\/2162402X.2015.1027473"},{"key":"97390_CR28","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1172\/JCI120358","volume":"128","author":"Y Zohar","year":"2018","unstructured":"Zohar, Y. et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J. Clin. Invest. 128, 1200\u20131201 (2018).","journal-title":"J. Clin. Invest."},{"key":"97390_CR29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12885-018-4384-8","volume":"18","author":"C Zhang","year":"2018","unstructured":"Zhang, C. et al. CXCL9\/10\/11, a regulator of PD-L1 expression in gastric cancer. BMC Cancer 18, 462 (2018).","journal-title":"BMC Cancer"},{"key":"97390_CR30","doi-asserted-by":"crossref","unstructured":"Reynders, N. et al. The distinct roles of CXCR3 variants and their ligands in the tumor microenvironment. Cells 8 (2019).","DOI":"10.3390\/cells8060613"},{"key":"97390_CR31","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3804::AID-IMMU3804>3.0.CO;2-9","volume":"29","author":"B Lu","year":"1999","unstructured":"Lu, B. et al. Structure and function of the murine chemokine receptor CXCR3. Eur. J. Immunol. 29, 3804\u20133812 (1999).","journal-title":"Eur. J. Immunol."},{"key":"97390_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3892\/ol.2011.300","volume":"2","author":"M Liu","year":"2011","unstructured":"Liu, M., Guo, S. & Stiles, J. K. The emerging role of CXCL10 in cancer (Review). Oncol. Lett. 2, 583\u2013589 (2011).","journal-title":"Oncol. Lett."},{"key":"97390_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry, S. et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: Part 1: Assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv. Anat. Pathol. 24, 235\u2013251 (2017).","journal-title":"Adv. Anat. Pathol."},{"key":"97390_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","volume":"52","author":"MV Dieci","year":"2018","unstructured":"Dieci, M. V. et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin. Cancer Biol. 52, 16\u201325 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"97390_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-016-4072-9","volume":"161","author":"YR Chung","year":"2017","unstructured":"Chung, Y. R., Kim, H. J., Jang, M. H. & Park, S. Y. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status. Breast Cancer Res. Treat. 161, 409\u2013420 (2017).","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97390-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97390-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97390-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:22:54Z","timestamp":1670080974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97390-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97390"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97390-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]},"assertion":[{"value":"24 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18007"}}